Literature DB >> 15492359

Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals.

Antoni Noguera1, Claudia Fortuny, Carmen Muñoz-Almagro, Emilia Sanchez, M Antonia Vilaseca, Rafael Artuch, Jordi Pou, Rafael Jimenez.   

Abstract

OBJECTIVE: Exposure to nucleoside analogues in fetal or early life has been associated with rare clinically significant mitochondrial toxic effects, mainly neurologic symptoms. Lactate (LA) measurements have been used to monitor nucleoside-related mitochondrial toxicity. Our aim was to determine the prevalence, clinical evolution, and risk factors for hyperlactatemia in our cohort of human immunodeficiency virus (HIV)-uninfected children who were exposed to antiretrovirals.
METHODS: We conducted a prospective observational study of 127 HIV-uninfected infants who were born to HIV-infected women. Clinical symptoms suggesting mitochondrial dysfunction were analyzed in routine follow-up, and LA and alanine plasma levels were obtained at 6 weeks, 3 months, 6 months, and 12 months in all patients. Elevated alanine levels, together with hyperlactatemia, suggest chronic mitochondrial injury.
RESULTS: Most (85%) women received highly active antiretroviral therapy (HAART) during pregnancy (mean duration: 31 weeks) and zidovudine during labor (93%). Most (96%) children received zidovudine alone. Hyperlactatemia with hyperalaninemia was detected in 63 children in at least 1 of the measurements. Mean LA levels were significantly higher in children who were exposed to nucleoside analogue reverse transcriptase inhibitors than in control subjects (2.88 vs 1.61 at 6 weeks, 2.78 vs 1.49 at 3 months, 1.89 vs 1.39 at 6 months, and 1.71 vs 1.24 at 12 months; peak levels: 8.06, 10.1, 7.28, and 4.48 mmol/L, respectively). In 44 patients, LA levels progressed spontaneously to normality within the first year of life. Three girls presented a slight and self-limited delay in psychomotor development, with LA peak levels of 7.3, 4.0, and 4.6 mmol/L. Only the gestational use of didanosine was associated with a higher risk of hyperlactatemia.
CONCLUSIONS: In our series, almost half of the children (63 of 127) who were exposed to nucleoside analogues developed benign and self-limited hyperlactatemia. When symptomatic, nucleoside analogue-induced toxicity affected neurologic development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492359     DOI: 10.1542/peds.2004-0955

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

Review 1.  Treating HIV during pregnancy: an update on safety issues.

Authors:  D Heather Watts
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Zidovudine use in pregnancy and congenital malformations.

Authors:  Kathryn Rough; Jenny W Sun; George R Seage; Paige L Williams; Krista F Huybrechts; Brian T Bateman; Sonia Hernandez-Diaz
Journal:  AIDS       Date:  2017-07-31       Impact factor: 4.177

3.  Updates to the World Health Organization's Recommendations for the Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants.

Authors:  Christopher M Bositis; Ignace Gashongore; Devang M Patel
Journal:  Med J Zambia       Date:  2010

4.  Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean.

Authors:  Alicen B Spaulding; Qilu Yu; Lucy Civitello; Marisa M Mussi-Pinhata; Jorge Pinto; Ivete M Gomes; Jorge O Alarcón; George K Siberry; D Robert Harris; Rohan Hazra
Journal:  AIDS Res Hum Retroviruses       Date:  2016-04       Impact factor: 2.205

5.  Elevated Blood Mitochondrial DNA in Early Life Among Uninfected Children Exposed to Human Immunodeficiency Virus and Combination Antiretroviral Therapy in utero.

Authors:  Abhinav Ajaykumar; Mayanne Zhu; Fatima Kakkar; Jason Brophy; Ari Bitnun; Ariane Alimenti; Hugo Soudeyns; Sara Saberi; Arianne Y K Albert; Deborah M Money; Hélène C F Côté
Journal:  J Infect Dis       Date:  2021-02-24       Impact factor: 5.226

6.  Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast.

Authors:  Didier Koumavi Ekouevi; Ramata Touré; Renaud Becquet; Ida Viho; Charlotte Sakarovitch; François Rouet; Besigin Towne-Gold; Patricia Fassinou; Valériane Leroy; Stéphane Blanche; François Dabis
Journal:  Pediatrics       Date:  2006-09-01       Impact factor: 7.124

Review 7.  HIV-exposed uninfected children: a growing population with a vulnerable immune system?

Authors:  L Afran; M Garcia Knight; E Nduati; B C Urban; R S Heyderman; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

8.  Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity.

Authors:  Andrea L Ciaranello; George R Seage; Kenneth A Freedberg; Milton C Weinstein; Shahin Lockman; Rochelle P Walensky
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

9.  Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy.

Authors:  Grace A McComsey; Minhee Kang; Allison C Ross; Dirk Lebrecht; Elizabeth Livingston; Ann Melvin; Jane Hitti; Susan E Cohn; Ulrich A Walker
Journal:  HIV Clin Trials       Date:  2008 Mar-Apr

10.  Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.

Authors:  Salina M Torres; Dale M Walker; Consuelo L McCash; Meghan M Carter; Jessica Ming; Edmund M Cordova; Rachel M Pons; Dennis L Cook; Steven K Seilkop; William C Copeland; Vernon E Walker
Journal:  Environ Mol Mutagen       Date:  2009-01       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.